EOLS
Price
$7.52
Change
-$0.06 (-0.79%)
Updated
Aug 28 closing price
Capitalization
486.43M
74 days until earnings call
LNTH
Price
$55.50
Change
-$1.34 (-2.36%)
Updated
Aug 28 closing price
Capitalization
3.77B
62 days until earnings call
Interact to see
Advertisement

EOLS vs LNTH

Header iconEOLS vs LNTH Comparison
Open Charts EOLS vs LNTHBanner chart's image
Evolus
Price$7.52
Change-$0.06 (-0.79%)
Volume$679.8K
Capitalization486.43M
Lantheus Holdings
Price$55.50
Change-$1.34 (-2.36%)
Volume$1.06M
Capitalization3.77B
EOLS vs LNTH Comparison Chart in %
Loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EOLS vs. LNTH commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a StrongBuy and LNTH is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (EOLS: $7.52 vs. LNTH: $55.50)
Brand notoriety: EOLS and LNTH are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EOLS: 46% vs. LNTH: 62%
Market capitalization -- EOLS: $486.43M vs. LNTH: $3.77B
EOLS [@Pharmaceuticals: Generic] is valued at $486.43M. LNTH’s [@Pharmaceuticals: Generic] market capitalization is $3.77B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileLNTH’s FA Score has 0 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • LNTH’s FA Score: 0 green, 5 red.
According to our system of comparison, LNTH is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 5 TA indicator(s) are bullish while LNTH’s TA Score has 5 bullish TA indicator(s).

  • EOLS’s TA Score: 5 bullish, 3 bearish.
  • LNTH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both EOLS and LNTH are a good buy in the short-term.

Price Growth

EOLS (@Pharmaceuticals: Generic) experienced а +1.28% price change this week, while LNTH (@Pharmaceuticals: Generic) price change was -6.19% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.61%. For the same industry, the average monthly price growth was +12.19%, and the average quarterly price growth was +85.29%.

Reported Earning Dates

EOLS is expected to report earnings on Nov 11, 2025.

LNTH is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LNTH($3.77B) has a higher market cap than EOLS($486M). EOLS YTD gains are higher at: -31.884 vs. LNTH (-37.961). LNTH has higher annual earnings (EBITDA): 457M vs. EOLS (-33.58M). LNTH has more cash in the bank: 696M vs. EOLS (61.7M). EOLS has less debt than LNTH: EOLS (155M) vs LNTH (615M). LNTH has higher revenues than EOLS: LNTH (1.52B) vs EOLS (278M).
EOLSLNTHEOLS / LNTH
Capitalization486M3.77B13%
EBITDA-33.58M457M-7%
Gain YTD-31.884-37.96184%
P/E RatioN/A14.76-
Revenue278M1.52B18%
Total Cash61.7M696M9%
Total Debt155M615M25%
FUNDAMENTALS RATINGS
EOLS vs LNTH: Fundamental Ratings
EOLS
LNTH
OUTLOOK RATING
1..100
259
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
7161
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9191
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LNTH's Valuation (60) in the Medical Specialties industry is in the same range as EOLS (92) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew similarly to EOLS’s over the last 12 months.

LNTH's Profit vs Risk Rating (61) in the Medical Specialties industry is in the same range as EOLS (71) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew similarly to EOLS’s over the last 12 months.

LNTH's SMR Rating (100) in the Medical Specialties industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew similarly to EOLS’s over the last 12 months.

LNTH's Price Growth Rating (91) in the Medical Specialties industry is in the same range as EOLS (91) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew similarly to EOLS’s over the last 12 months.

LNTH's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that LNTH’s stock grew similarly to EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSLNTH
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
67%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 3 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRIQX12.22N/A
N/A
Fidelity Advisor Real Estate Income M
AEGSX35.58N/A
N/A
Invesco International Value R6
WMKSX17.49N/A
N/A
WesMark Small Company Fund
BRXCX15.85N/A
N/A
MFS Blended Research Intl Eq C
MGKIX14.65N/A
N/A
Morgan Stanley Global Permanence I

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
-0.79%
PRGO - EOLS
44%
Loosely correlated
-0.54%
AMRX - EOLS
33%
Loosely correlated
+2.03%
LNTH - EOLS
33%
Poorly correlated
-2.36%
ALKS - EOLS
31%
Poorly correlated
-1.09%
HROW - EOLS
28%
Poorly correlated
+0.52%
More

LNTH and

Correlation & Price change

A.I.dvisor tells us that LNTH and EOLS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LNTH and EOLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LNTH
1D Price
Change %
LNTH100%
-2.36%
EOLS - LNTH
33%
Poorly correlated
-0.79%
ACET - LNTH
32%
Poorly correlated
+0.40%
CRDL - LNTH
28%
Poorly correlated
-2.68%
SNDL - LNTH
26%
Poorly correlated
+6.32%
LFCR - LNTH
24%
Poorly correlated
+1.20%
More